Black Rock Inc. Biocryst Pharmaceuticals Inc Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Black Rock Inc. holds 19,956,255 shares of BCRX stock, worth $149 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,956,255
Previous 18,440,729
8.22%
Holding current value
$149 Million
Previous $93.7 Million
31.65%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BCRX
# of Institutions
279Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$151 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$88.5 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$67.8 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$66 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$60.7 Million1.15% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.39B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...